GU Cancers 2023 | Toxicity management and monitoring during bladder cancer treatment
Arlene Siefker-Radtke
• 16 Feb 2023
Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses toxicity management and monitoring during bladder cancer treatment. Enfortumab vedotin generates positive responses in patient with bladder cancer, however, treatment should be avoided in patients with liver sclerosis. Dr Siefker-Radtke additionally talks on toxicity management of sacituzumab govitecan and erdafitinib. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
